- Home
- NAC vs SUPN Comparison
NAC vs SUPN Comparison
Compare NAC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAC
- SUPN
- Stock Information
- Founded
- NAC 1998
- SUPN 2005
- Country
- NAC France
- SUPN United States
- Employees
- NAC N/A
- SUPN N/A
- Industry
- NAC Investment Managers
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- NAC Finance
- SUPN Health Care
- Exchange
- NAC Nasdaq
- SUPN Nasdaq
- Market Cap
- NAC 1.6B
- SUPN 1.7B
- IPO Year
- NAC N/A
- SUPN 2012
- Fundamental
- Price
- NAC $11.19
- SUPN $32.29
- Analyst Decision
- NAC
- SUPN Hold
- Analyst Count
- NAC 0
- SUPN 2
- Target Price
- NAC N/A
- SUPN $36.00
- AVG Volume (30 Days)
- NAC 307.3K
- SUPN 704.1K
- Earning Date
- NAC 01-01-0001
- SUPN 05-07-2025
- Dividend Yield
- NAC 4.33%
- SUPN N/A
- EPS Growth
- NAC N/A
- SUPN 6500.00
- EPS
- NAC N/A
- SUPN 1.32
- Revenue
- NAC N/A
- SUPN $661,817,000.00
- Revenue This Year
- NAC N/A
- SUPN N/A
- Revenue Next Year
- NAC N/A
- SUPN $8.67
- P/E Ratio
- NAC N/A
- SUPN $24.46
- Revenue Growth
- NAC N/A
- SUPN 8.94
- 52 Week Low
- NAC $9.32
- SUPN $25.53
- 52 Week High
- NAC $11.21
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- NAC 37.04
- SUPN 43.82
- Support Level
- NAC $11.15
- SUPN $31.74
- Resistance Level
- NAC $11.36
- SUPN $33.56
- Average True Range (ATR)
- NAC 0.07
- SUPN 0.94
- MACD
- NAC -0.02
- SUPN 0.27
- Stochastic Oscillator
- NAC 10.27
- SUPN 54.15
About NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.